Stock Scorecard
Stock Summary for Karyopharm Therapeutics Inc (KPTI) - $5.75 as of 12/8/2025 3:42:47 PM EST
Total Score
8 out of 30
Safety Score
26 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for KPTI
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for KPTI
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for KPTI
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for KPTI
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for KPTI (26 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for KPTI
Financial Details for KPTI
Company Overview |
|
|---|---|
| Ticker | KPTI |
| Company Name | Karyopharm Therapeutics Inc |
| Country | USA |
| Description | Karyopharm Therapeutics Inc. is a biopharmaceutical company based in Newton, Massachusetts, that focuses on innovative cancer therapies through its proprietary SINE™ (Selective Inhibitor of Nuclear Export) technology platform. The company’s lead product, Xpovio (selinexor), has garnered multiple regulatory approvals, reflecting its dedication to addressing unmet medical needs in oncology. With a strong drug development pipeline and an emphasis on advancing treatment modalities, Karyopharm is strategically positioned to significantly enhance patient outcomes in cancer care. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 5.75 |
| Price 4 Years Ago | 96.45 |
| Last Day Price Updated | 12/8/2025 3:42:47 PM EST |
| Last Day Volume | 148,612 |
| Average Daily Volume | 122,741 |
| 52-Week High | 12.45 |
| 52-Week Low | 3.51 |
| Last Price to 52 Week Low | 63.82% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 47.47 |
| Sector PE | 89.35 |
| 5-Year Average PE | -18.77 |
| Free Cash Flow Ratio | 2.60 |
| Industry Free Cash Flow Ratio | 14.06 |
| Sector Free Cash Flow Ratio | 28.79 |
| Current Ratio Most Recent Quarter | 1.03 |
| Total Cash Per Share | 2.21 |
| Book Value Per Share Most Recent Quarter | -30.94 |
| Price to Book Ratio | 12.05 |
| Industry Price to Book Ratio | 34.08 |
| Sector Price to Book Ratio | 33.16 |
| Price to Sales Ratio Twelve Trailing Months | 0.71 |
| Industry Price to Sales Ratio Twelve Trailing Months | 31.69 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.82 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
| Total Shares Outstanding | 17,050,900 |
| Market Capitalization | 98,042,675 |
| Institutional Ownership | 32.68% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 46.60% |
| Reported EPS 12 Trailing Months | -14.70 |
| Reported EPS Past Year | -10.66 |
| Reported EPS Prior Year | -7.67 |
| Net Income Twelve Trailing Months | -124,621,000 |
| Net Income Past Year | -76,422,000 |
| Net Income Prior Year | -143,099,000 |
| Quarterly Revenue Growth YOY | 13.60% |
| 5-Year Revenue Growth | 28.85% |
| Operating Margin Twelve Trailing Months | -34.60% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 37,672,000 |
| Total Cash Past Year | 62,476,000 |
| Total Cash Prior Year | 52,231,000 |
| Net Cash Position Most Recent Quarter | -139,071,000 |
| Net Cash Position Past Year | -100,472,000 |
| Long Term Debt Past Year | 162,948,000 |
| Long Term Debt Prior Year | 170,919,000 |
| Total Debt Most Recent Quarter | 176,743,000 |
| Equity to Debt Ratio Past Year | 0.00 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -186,017,000 |
| Total Stockholder Equity Prior Year | -136,206,000 |
| Total Stockholder Equity Most Recent Quarter | -269,258,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -89,404,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -5.24 |
| Free Cash Flow Past Year | -127,628,000 |
| Free Cash Flow Prior Year | -92,723,000 |
Options |
|
| Put/Call Ratio | 2.14 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.10 |
| MACD Signal | -0.09 |
| 20-Day Bollinger Lower Band | 4.07 |
| 20-Day Bollinger Middle Band | 5.74 |
| 20-Day Bollinger Upper Band | 7.41 |
| Beta | 0.23 |
| RSI | 44.55 |
| 50-Day SMA | 6.34 |
| 150-Day SMA | 17.40 |
| 200-Day SMA | 34.40 |
System |
|
| Modified | 12/9/2025 3:12:11 AM EST |